This review outlines individualized management for narcolepsy type 1 (NT1), including pharmacological and non-pharmacological strategies, and critically evaluates emerging therapies such as orexin-targeted drugs, immunotherapies, and cell/gene-based treatments. The gene discussed is HCRT; the disease is narcolepsy-cataplexy syndrome.